ALEMBIC PHARMA has announced its results for the year ended March 2019. Let us have a look at the detailed performance review of the company during FY18-19.
No. of Mths Year Ending | 12 Mar-18* | 12 Mar-19* | % Change | |
---|---|---|---|---|
Net Sales | Rs m | 31,308 | 39,347 | 25.7% |
Other income | Rs m | 70 | 94 | 33.4% |
Total Revenues | Rs m | 31,378 | 39,441 | 25.7% |
Gross profit | Rs m | 6,431 | 8,736 | 35.8% |
Depreciation | Rs m | 1,055 | 1,152 | 9.3% |
Interest | Rs m | 34 | 184 | 441.5% |
Profit before tax | Rs m | 5,413 | 7,493 | 38.4% |
Tax | Rs m | 1,204 | 1,568 | 30.2% |
Profit after tax | Rs m | 4,128 | 5,844 | 41.6% |
Gross profit margin | % | 20.5 | 22.2 | |
Effective tax rate | % | 22.2 | 20.9 | |
Net profit margin | % | 13.2 | 14.8 |
No. of Mths Year Ending | 12 Mar-18* | 12 Mar-19* | % Change | |
---|---|---|---|---|
Networth | Rs m | 22,201 | 27,188 | 22.5 |
Current Liabilities | Rs m | 11,235 | 14,896 | 32.6 |
Long-term Debt | Rs m | 5,000 | 4,993 | -0.1 |
Total Liabilities | Rs m | 39,411 | 47,778 | 21.2 |
Current assets | Rs m | 18,247 | 19,577 | 7.3 |
Fixed Assets | Rs m | 20,035 | 27,097 | 35.2 |
Total Assets | Rs m | 39,411 | 47,778 | 21.2 |
Particulars | No. of months | 12 | 12 | % Change |
---|---|---|---|---|
Year Ending | Mar-18 | Mar-19 | ||
Cash Flow from Operating Activities | Rs m | 3,124 | 8,120 | 159.9% |
Cash Flow from Investing Activities | Rs m | -8,844 | -7,556 | - |
Cash Flow from Financing Activities | Rs m | 5,026 | 590 | -88.3% |
Net Cash Flow | Rs m | -693 | 1,153 | - |
No. of Mths Year Ending | 12 Mar-18* | 12 Mar-19* | |
---|---|---|---|
Sales per share (Unadj.) | Rs | 166.1 | 208.7 |
TTM Earnings per share | Rs | 21.9 | 31.0 |
Diluted earnings per share | Rs | 21.9 | 31.0 |
Price to Cash Flow | x | 17.9 | 13.3 |
TTM P/E ratio | x | 15.9 | 15.9 |
Price / Book Value ratio | x | 4.7 | 3.7 |
Market Cap | Rs m | 94,288 | 94,288 |
Dividends per share (Unadj.) | Rs | 4.0 | 5.5 |
Current Ratio: The company's current ratio deteriorated and stood at 1.3x during FY19, from 1.6x during FY18. The current ratio measures the company's ability to pay short-term and long-term obligations.
Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 41.7x during FY19, from 160.2x during FY18. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.
Return on Equity (ROE): The ROE for the company improved and stood at 21.5% during FY19, from 18.6% during FY19. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.
Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 23.6% during FY19, from 19.7% during FY18. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.
Return on Assets (ROA): The ROA of the company improved and stood at 12.6% during FY19, from 10.6% during FY18. The ROA measures how efficiently the company uses its assets to generate earnings.
No. of Mths Year Ending | 12 Mar-18* | 12 Mar-19* | |
---|---|---|---|
Current ratio | x | 1.6 | 1.3 |
Debtors’ Days | Days | 61 | 45 |
Interest coverage | x | 160.2 | 41.7 |
Debt to equity ratio | x | 0.2 | 0.2 |
Return on assets | % | 10.6 | 12.6 |
Return on equity | % | 18.6 | 21.5 |
Return on capital employed | % | 19.7 | 23.6 |
To see how ALEMBIC PHARMA has performed over the last 5 years, please visit here.
Over the last one year, ALEMBIC PHARMA share price has moved up from Rs 490.3 to Rs 500.2, registering a gain of Rs 9.9 or around 2.0%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,997.8 (down 0.4%). Over the last one year it has moved down from 13,835.1 to 12,997.8, a loss of 837 points (down 6.1%).
Overall, the S&P BSE SENSEX is up 11.2% over the year.
(To know more, check out historical annual results for ALEMBIC PHARMA and quarterly results for ALEMBIC PHARMA)
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More
Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA 2018-19 Annual Report Analysis". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!